Evidence map›Paper›PMID 40975066›Full record

ArticleCell reports. Medicine2025

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer.

Si Shi, Jian Zhang, Rujiao Liu, Shuiping Gao, Jin Xu, Wei Wang, Miaoyan Wei, Jialin Li, Chen Liu, Xiaowu Xu and 9 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Si ShiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jian ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Rujiao LiuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuiping GaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jin XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Wei WangDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Miaoyan WeiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jialin LiDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Chen LiuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaowu XuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Wentao PanAscentage Pharma (Suzhou) Co., Ltd., Suzhou, China.
Xiaohong TianAscentage Pharma (Suzhou) Co., Ltd., Suzhou, China.
Lichuang MenAscentage Pharma (Suzhou) Co., Ltd., Suzhou, China.
Hengbang WangAscentage Pharma (Suzhou) Co., Ltd., Suzhou, China.
Zhiyan LiangAscentage Pharma Group Inc., Rockville, MD, USA.
Min ZhuAscentage Pharma Group Inc., Rockville, MD, USA.
Dajun YangAscentage Pharma (Suzhou) Co., Ltd., Suzhou, China; Department of Experimental Research, State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yifan ZhaiAscentage Pharma Group Inc., Rockville, MD, USA. Electronic address: yzhai@ascentage.com.
XianJun YuDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: yuxianjun@fudanpci.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced pancreatic cancer presents dismal survival with limited effective, well-tolerated options beyond chemotherapy. This phase 1 trial evaluates the safety, tolerability, and efficacy of bivalent IAP antagonist APG-1387 with nab-paclitaxel and gemcitabine (AG) in patients failing or intolerant to standard care. In 28-day cycles, patients receive intravenous infusions of APG-1387 (20, 30, or 45 mg) on days 1, 8, 15, and 22, and nab-paclitaxel (125 mg/m

Indexed as

AlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidinePaclitaxelPancreatic NeoplasmsAdultAgedFemaleGemcitabineHumansMaleMiddle AgedNeoplasm Metastasis130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineGemcitabinePaclitaxelantitumor activitychemotherapyIAP inhibitorpancreatic cancerphase 1 trial

Identifiers

PMID40975066
PMCPMC12629782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.